Overview

A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

Status:
Active, not recruiting
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.
Phase:
Phase 1
Details
Lead Sponsor:
Oxford BioMedica